New asthma therapy? Approved drugs show promise

"If this research proves successful, we may be just a few years away from a new treatment for asthma," says Samantha Walker. (Credit: Rob Allen/Flickr)

Researchers have identified the potential root cause of asthma and are testing a class of drugs—initially developed to treat osteoporosis—that may reverse symptoms.

“Our findings are incredibly exciting,” says Daniela Riccardi, a professor from Cardiff University School of Biosciences and the study’s principal investigator. “For the first time we have found a link [to] airways inflammation, which can be caused by environmental triggers—such as allergens, cigarette smoke, and car fumes—and airways twitchiness in allergic asthma.

In a paper published in Science Translational Medicine, Riccardi and colleagues at King’s College London and the Mayo Clinic describe the previously unproven role of the calcium sensing receptor (CaSR) in causing asthma, a disease which affects 300 million people worldwide.

The team used mouse models of asthma and human airway tissue from asthmatic and non-asthmatic people to reach their findings.

Crucially, the paper highlights the effectiveness of a class of drugs known as calcilytics in manipulating CaSR to reverse all symptoms associated with the condition.

“Our paper shows how these triggers release chemicals that activate CaSR in airway tissue and drive asthma symptoms like airway twitchiness, inflammation, and narrowing. Using calcilytics, nebulized directly into the lungs, we show that it is possible to deactivate CaSR and prevent all of these symptoms,” says Riccardi.

New treatments needed

Samantha Walker, director of research and policy at Asthma UK, which helped fund the research, says the work allows researchers for the first time to tackle the underlying causes of asthma symptoms.

“Five percent of people with asthma don’t respond to current treatments so research breakthroughs could be life changing for hundreds of thousands of people,” says Walker.

“If this research proves successful, we may be just a few years away from a new treatment for asthma, and we urgently need further investment to take it further through clinical trials.

“Asthma research is chronically underfunded; there have only been a handful of new treatments developed in the last 50 years so the importance of investment in research like this is absolutely essential.”

While asthma is well controlled in some people, around one-in-twelve patients respond poorly to current treatments. This significant minority accounts for around 90 percent of health care costs associated with the condition.

According to Cardiff University Professor Paul Kemp, who coauthored the study, the identification of CaSR in airway tissue means the potential to treat of other inflammatory lung diseases beyond asthma is immense. These include chronic obstructive pulmonary disease (COPD) and chronic bronchitis, for which currently there exists no cure.

Funding for clinical trials

Riccardi and collaborators are now seeking funding to determine the efficacy of calcilytic drugs in treating asthmas that are especially difficult to treat, particularly steroid-resistant and influenza-exacerbated asthma, and to test these drugs in patients with asthma.


Calcilytics were first developed for the treatment of osteoporosis around 15 years ago with the aim of strengthening deteriorating bone by targeting CaSR to induce the release of an anabolic hormone. Although clinically safe and well tolerated in people, calcilytics proved unsuccessful in treating osteoporosis.

But this latest breakthrough has provided researchers with the unique opportunity to re-purpose these drugs, potentially accelerating the time it takes for them to be approved for use asthma patients.

Once funding has been secured, the group aim to be trialing the drugs on humans within two years.

“If we can prove that calcilytics are safe when administered directly to the lung in people, then in five years we could be in a position to treat patients and potentially stop asthma from happening in the first place,” adds Riccardi.

Source: Cardiff University